MUC4 and neoplasm: Patients with MUC4 and KMT2C mutations, both positive-predictive markers, showed no enrichment of anti-tumor immune subsets with the exception of DC-LAMP+ cells, which were also the only immune-enriched cell-type across AXL IC-positive, PDL1 TPS-high and TMB-high patients (Figure 6, Box 20), suggesting that the DC-LAMP+ cluster captures immune-activating mregDCs.